Associate Medical Director/Medical Director, Oncology at Corcept Therapeutics

Redwood City, California, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, Pharmaceuticals, OncologyIndustries

Requirements

MD required
Board eligible or certified in an internal medicine subspecialty required; oncology/hematology board certification/eligibility preferred
2+ years’ clinical development experience in the biotechnology/pharmaceutical industry or an academic clinical trial unit
A proven track record of scholarly clinical research demonstrated by publications in top tier journals
Excellent communicators with proven leadership skills and the ability to successfully interact in a busy cross functional environment
Ability to establish and maintain a team "sense of urgency" around timelines

Responsibilities

Act as clinical expert for both internal Company team members and for external contacts related to the assigned therapeutic programs
Provide clinical and scientific leadership including training and ongoing input, to members of the Development and product Core Teams on issues related to the therapeutic field
Provide medical oversight for Company operational staff, CROs and clinical trial sites in areas related to the oncology programs
Design the clinical development plan for indications relevant to assigned molecules programs and support the assessment of the development plans through the cross-functional product core team
Design, develop and implement clinical studies for the applicable drug candidate, from Phase I through Phase III
Establish relationships with external experts in the scientific oncology areas, including principal investigators and opinion leaders, to facilitate scientific excellence in clinical trials research
Establish and approve scientific methods for design and implementation of applicable clinical protocols, data collection systems and final reports
Participate in the writing and review of clinical protocols, investigator brochures, clinical study reports, publications and other documents
Deliver timely and high quality clinical data
Provide medical oversight and safety monitoring for ongoing clinical trials including participation in SAE reporting and serving on the safety committee
Participate in appropriate regulatory discussion and activities, including the filing of IND’s, CTXs, NDA/MAAs, throughout the development cycle
Participate in clinical study report conceptualization, development and writing for global regulatory submissions
Other duties as assigned

Skills

Oncology

Clinical Development

Clinical Trials

CRO Oversight

Drug Development

Phase I

Medical Oversight

Scientific Leadership

Glucocorticoid Receptor

Cortisol Modulators

Corcept Therapeutics

Develops cortisol modulators for medical conditions

About Corcept Therapeutics

Corcept Therapeutics focuses on developing treatments that regulate cortisol levels in the body, which is important for managing various health issues. Their main product, Korlym, is used to treat Cushing's syndrome, a condition caused by too much cortisol. Korlym was approved by the FDA in 2012 and is the first medication specifically for this disorder. Corcept stands out from competitors by having a strong emphasis on research and development, having discovered over 1,000 unique cortisol modulators. The company aims to expand its range of treatments while also providing educational resources to healthcare professionals and patients to improve understanding and care for cortisol-related conditions.

Menlo Park, CaliforniaHeadquarters

1998Year Founded

$39.7MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

Remote Work Options

Flexible Work Hours

Risks

Teva's antitrust lawsuit could lead to legal expenses and market share loss.

Heavy reliance on Korlym makes Corcept vulnerable to market fluctuations.

Recent investments may pressure Corcept for short-term financial performance, impacting R&D.

Differentiation

Corcept specializes in cortisol modulation, a niche with few direct competitors.

Korlym is the first FDA-approved treatment for Cushing's syndrome, a significant market advantage.

Corcept's extensive R&D has led to the discovery of over 1,000 selective cortisol modulators.

Upsides

Increased interest in cortisol therapies for mental health boosts Corcept's R&D prospects.

Advancements in drug delivery systems could enhance Corcept's product efficacy.

The FDA's fast-track designation supports Corcept's innovative cortisol-related treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free